Replies to post #238046 on Biotech Values

[DewDiligence]

ARPO +63%(!?) on_filing_of_proxy_for_previously-announced_revere-merger:

https://www.sec.gov/Archives/edgar/data/1422142/000119312521210402/d187261ddefm14a.htm

The shareholder vote is on 8/17/21.

[DewDiligence]

ARPO—>AADI—following_1:15_reverse_split—pursuant_to previously_announced_reverse-merger:

https://finance.yahoo.com/news/aadi-bioscience-announces-closing-merger-200500624.html

[DewDiligence]

AADI—(-25%/AH)—halts_phase-2_trial_for utility—reduces workforce 80%:

https://www.prnewswire.com/news-releases/aadi-bioscience-provides-precision1-trial-and-corporate-updates-302226818.html

AADI, itself the product of a 2021 reverse-merger (#msg-163841604), is now a candidate for a reverse-merger from the opposite side. AADI had ~$70M of net cash at 6/30/24, but little prospect of becoming a profitable business. AADI’s sole approved drug, Fyarro, did a paltry $6M in 2Q24 sales. The approved indication is rare: advanced malignant perivascular epithelioid sarcoma.